GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiangxue Pharmaceutical Co Ltd (SZSE:300147) » Definitions » Capex-to-Operating-Cash-Flow

Xiangxue Pharmaceutical Co (SZSE:300147) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Xiangxue Pharmaceutical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Xiangxue Pharmaceutical Co's Capital Expenditure for the three months ended in Sep. 2024 was ¥-4.29 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was ¥-29.53 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Xiangxue Pharmaceutical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xiangxue Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Xiangxue Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.96 2.35 1.96 1.62 0.21

Xiangxue Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.21 0.68 - -

Competitive Comparison of Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.



Xiangxue Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-56.034) / 263.442
=0.21

Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-4.287) / -29.53
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xiangxue Pharmaceutical Co  (SZSE:300147) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Xiangxue Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Xiangxue Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Xiangxue Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No 2 Jinfeng Road , Science City, Guangzhou Economic and Technological Development Z, Guangzhou, CHN, 510663
Xiangxue Pharmaceutical Co Ltd is a China-based company engages in the manufacture and distribution of pharmaceutical products. Its diversified healthcare portfolio includes Chinese Herbal Slices, TCM, Life Science, Biomedical Engineering health solutions (food and beverage), healthcare supplements and so on.
Executives
Huang Wei Hua Supervisors
Tan Wen Hui Director
Kang Zhi Ying Executives
Ceng Lun Executives
Liu Yan Executives
Lu Feng Executives
Xu Li Secretary, Director
Mo Zi Yu Supervisors
Mai Zhen Jiang Supervisors
Wang Yong Hui Directors, executives
He Tao Executives
Fang Wei Min Supervisors
Huang Bin Directors, Directors, and Executives
Wu Jun Executives
Chen Wen Jin Executives

Xiangxue Pharmaceutical Co Headlines

No Headlines